A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

• ClinicalTrials.gov Identifier: NCT04594798
• Recruitment Status: Recruiting
• First Posted: October 20, 2020
• Last Update Posted: January 11, 2022
• Sponsor: University of Rochester
• Collaborator: Genentech, Inc.
• Information provided by (Responsible Party): Patrick Reagan, University of Rochester

Study Description

Brief Summary:

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Condition or disease	Intervention/treatment	Phase
DLBCL; Lymphoma, B-Cell	Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone	Phase 2

Detailed Description:

In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 39 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
• Actual Study Start Date: September 20, 2021
• Estimated Primary Completion Date: July 31, 2024
• Estimated Study Completion Date: July 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Experimental: Polatuzumab Vedotin and R-CHOP; The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)	Drug: Polatuzumab vedotin; IV 1.8 mg/kg per cycle; Drug: Rituximab; IV 375 mg/m2 per cycle; Drug: Cyclophosphamide; IV 400 mg/m2 per cycle; Drug: Doxorubicin; IV 25 mg/m2 per cycle; Drug: Prednisone; PO 40 mg/m2 per cycle

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
   Measure of time from study enrollment until progression.

Secondary Outcome Measures :

1. Overall Survival [ Time Frame: From date of enrollment until date of death from any cause up to 24 months ]
   Measure of time from study enrollment until death from any cause.

Eligibility Criteria

• Ages Eligible for Study: 75 Years and older (Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Subjects must be able to understand and be willing to sign the written informed consent form.
• Men and women aged greater than or equal to 75 years of age
• ECOG performance status of 0-3

• Histologically-confirmed DLBCL, NOS, NOS, high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements, high grade B-cell lymphoma, NOS, and grade 3b follicular lymphoma by 2016 WHO classification by site hematopathologist

  • Histologic transformation (HT) will be included on the study. This must be confirmed with a biopsy. Patients with HT may have received prior treatment for indolent lymphoma including chemoimmunotherapy, but must not have received an anthracycline-containing regimen in the past. Patients with Richter's transformation will be eligible.
  • Composite and discordant lymphomas containing both indolent and large cell features will be included

• Has received no prior therapy for aggressive B-cell lymphoma or HT with the following exceptions:

  • A course of corticosteroids given for lymphoma related symptoms.
  • A course of cyclophosphamide or vincristine with or without steroids given for lymphoma related symptoms.
  • One cycle of anthracycline containing chemotherapy such as R-CHOP or R-miniCHOP given urgently for aggressive disease.

Patient is not felt to be a candidate for standard dose R-CHOP due to age or comorbidities, per the site investigator.

• Ejection fraction of ≥ 45% on echocardiogram or MUGA
• Patient has a platelet count of ≥75,000/μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
• Patient has an absolute neutrophil count of ≥1,500/ μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
• Patient has a calculated or measured creatinine clearance of >30 mL/minute within 14 days before enrollment.
• Total bilirubin must be less than 1.5 times the upper limit of normal (ULN) unless the elevation is known to be due to Gilbert syndrome or hepatic involvement with aggressive B-cell lymphoma in which case it can be ≤ 3.0 times the ULN.
• ALT or AST must be ≤ 2.5 times the ULN.

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

  • With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 months after the last dose of polatuzumab vedotin to avoid exposing the embryo or fetus for the duration of the pregnancy. Men must refrain from donating sperm during this same period.
  • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. Male patients considering preservation of fertility should bank sperm before study treatment.

Exclusion Criteria:

• History of, or clinically apparent central nervous system (CNS) lymphoma
• Primary mediastinal B-cell lymphoma or EBV positive DLBCL
• Patient is receiving peritoneal dialysis or hemodialysis
• Patient has > Grade 1 peripheral neuropathy.
• New York Heart Association class III heart failure or EF <45%
• Patient has received other investigational drugs with 14 days before enrollment
• Prior exposure to anthracycline except for one cycle of therapy given urgently for lymphoma.

• Patient has concomitant active malignancy that the treating physician or PI feels may interfere with the ability to measure the primary or secondary outcomes

  • Patients with stage 1 cancers are eligible after definitive treatment.
  • Patients with low grade prostate cancer who are managed with observation are eligible.
  • Patients with other malignancies that have been treated with curative intent will be included if they are in documented remission without treatment for ≥ 3 years prior to enrollment.
• Patient is known to be HIV positive (test result not required for enrollment).
• Patient has active hepatitis B with a positive surface antigen or viral load. Carriers of hepatitis B virus should be closely monitored for clinical and laboratory signs of active HBV infection and for signs of hepatitis throughout study participation according to national and local guidelines. Those at high risk of reactivation should be placed on appropriate antiviral therapy as per national guidelines.
• History of solid organ transplantation, or post-transplant lymphoproliferative disorder
• Patient has history of allogeneic stem cell transplantation.
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse

Contacts and Locations

Contacts

Contact: Krista French; (585) 276-5812; Krista_French@URMC.Rochester.edu

Locations

United States, New York

University of Rochester; Recruiting

Rochester, New York, United States, 14642

Sponsors and Collaborators

University of Rochester

Genentech, Inc.

Investigators

• Principal Investigator: Patrick Reagan; University of Rochester

More Information

• Responsible Party: Patrick Reagan, Assistant Professor - Department of Medicine , Hematology/Oncology (SMD), University of Rochester
• ClinicalTrials.gov Identifier: NCT04594798
• Other Study ID Numbers: ULYM20030
• First Posted: October 20, 2020
• Last Update Posted: January 11, 2022
• Last Verified: January 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Patrick Reagan, University of Rochester:

polatuzumab vedotin; rituximab; cyclophosphamide; doxorubicin; prednisone; R-miniCHP; DLBCL; Lymphoma, B-Cell

Additional relevant MeSH terms:

Lymphoma, B-Cell; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin; Prednisone; Cyclophosphamide; Rituximab; Doxorubicin; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Anti-Inflammatory Agents; Glucocorticoids; Hormones